Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for Compass Therapeutics in a note issued to investors on Monday, October 6th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings per share of ($0.13) for the quarter. Lifesci Capital has a "Outperform" rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Lifesci Capital also issued estimates for Compass Therapeutics' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.49) EPS.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01).
Other equities research analysts have also issued reports about the company. Compass Point set a $10.00 target price on Compass Therapeutics in a research report on Monday. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 target price on the stock in a research report on Tuesday, July 1st. Guggenheim raised their price target on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a report on Wednesday. Finally, D. Boral Capital reissued a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $13.10.
Get Our Latest Analysis on Compass Therapeutics
Compass Therapeutics Price Performance
Shares of NASDAQ CMPX opened at $3.90 on Thursday. Compass Therapeutics has a 1-year low of $1.27 and a 1-year high of $4.08. The business's fifty day moving average price is $3.31 and its two-hundred day moving average price is $2.62. The firm has a market capitalization of $539.30 million, a PE ratio of -8.67 and a beta of 1.48.
Hedge Funds Weigh In On Compass Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new position in shares of Compass Therapeutics in the 2nd quarter valued at $30,000. Strs Ohio acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at $34,000. Squarepoint Ops LLC acquired a new stake in Compass Therapeutics during the 4th quarter worth about $35,000. Birchview Capital LP acquired a new stake in Compass Therapeutics during the 1st quarter worth about $46,000. Finally, Walleye Trading LLC acquired a new stake in Compass Therapeutics during the 1st quarter worth about $48,000. Institutional investors and hedge funds own 68.43% of the company's stock.
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
